Avastin sBLA For Metastatic Breast Cancer Gets Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech reports that FDA has accepted its resubmitted application, which will be reviewed by the Oncologic Drugs Advisory Committee in December.
You may also be interested in...
FDA’s Oncologic Drugs Advisory Cmte. Will Review Avastin In Breast Cancer Dec. 5
ODAC will address Genentech’s sBLA for bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for locally recurrent or metastatic HER2 negative breast cancer.
FDA’s Oncologic Drugs Advisory Cmte. Will Review Avastin In Breast Cancer Dec. 5
ODAC will address Genentech’s sBLA for bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for locally recurrent or metastatic HER2 negative breast cancer.
Genentech Product Sales Rise 18 Percent, Led By Avastin, Though Lucentis A Disappointment
Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .